K. Kian Ang

K. Kian Ang's AcademicInfluence.com Rankings

K. Kian Ang

Medical

#2179

World Rank

#2583

Historical Rank

Oncology

#121

World Rank

#125

Historical Rank

medical Degrees

K. Kian Ang

Philosophy

#6340

World Rank

#9364

Historical Rank

Logic

#3518

World Rank

#4694

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is K. Kian Ang Influential?

(Suggest an Edit or Addition)

(See a Problem?)

K. Kian Ang's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
Human papillomavirus and survival of patients with oropharyngeal cancer. (2010) (4482)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010) (1824)
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 (1999) (1019)
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis (2006) (1005)
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. (2008) (970)
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. (2004) (672)
Validation of an accelerated ‘demons’ algorithm for deformable image registration in radiation therapy (2005) (658)
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. (2003) (640)
Radiation response of the central nervous system. (1995) (633)
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. (2014) (627)
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. (2009) (576)
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. (2009) (571)
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. (2000) (531)
Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. (2014) (521)
Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. (1993) (490)
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. (2006) (454)
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. (2012) (431)
The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. (1995) (409)
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. (2012) (399)
National Cancer Database report on cancer of the head and neck: 10‐Year update (2009) (369)
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. (1999) (365)
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (2014) (332)
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer (2001) (310)
Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). (2010) (304)
The epidermal growth factor receptor mediates radioresistance. (2003) (299)
Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes (2014) (299)
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. (2002) (294)
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. (2007) (281)
Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. (1997) (279)
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. (2012) (269)
TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence (2011) (257)
Sensitization of breast cancer cells to radiation by trastuzumab. (2003) (252)
Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. (2004) (237)
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. (2005) (228)
Apoptosis in irradiated murine tumors. (1991) (218)
Direct analysis of quantal radiation response data. (1986) (218)
Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-κB Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma (2006) (216)
IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. (2009) (213)
The essential role of radiation therapy in securing locoregional control of Merkel cell carcinoma. (1990) (212)
Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. (1993) (212)
Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module (2007) (210)
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. (2008) (206)
The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? (2011) (201)
Factors Associated with Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis (2008) (199)
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. (2008) (191)
A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (2011) (190)
Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. (2014) (190)
Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. (2006) (188)
Radiation-induced injury to the visual pathway. (1994) (184)
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. (2007) (181)
Extent and kinetics of recovery of occult spinal cord injury. (2001) (180)
Enhancement of tumor radioresponse in vivo by gemcitabine. (1999) (178)
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. (2016) (178)
Prognostic variables in parotid gland cancer. (1991) (177)
Precisely defining high‐risk operable head and neck tumors based on rtog #85‐03 and #88‐24: Targets for postoperative radiochemotherapy? (1998) (173)
Tissue tolerance to reirradiation. (2000) (173)
Postoperative radiotherapy for malignant tumors of the parotid gland. (1997) (170)
Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? (2001) (168)
Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. (2004) (166)
Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. (1997) (166)
Maxillary sinus carcinomas: natural history and results of postoperative radiotherapy. (1991) (165)
Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. (2008) (164)
Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. (1992) (162)
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. (2009) (161)
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. (2014) (160)
Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. (2009) (157)
Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. (2010) (155)
C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. (2001) (153)
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. (2009) (149)
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. (2009) (145)
The tolerance of primate spinal cord to re-irradiation. (1993) (140)
Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. (2005) (138)
Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. (2007) (136)
Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. (2004) (134)
An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma (2013) (134)
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. (2004) (133)
Head and Neck Cancers, Version 2.2013 (2013) (132)
Development of apoptosis in irradiated murine tumors as a function of time and dose. (1993) (131)
Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? (2003) (129)
Target cell and mode of radiation injury in rhesus salivary glands. (1986) (122)
ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. (1995) (115)
Maximizing therapeutic gain with gemcitabine and fractionated radiation. (1999) (112)
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. (1998) (112)
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. (2001) (109)
Radiotherapy for cancer of the head and neck: altered fractionation regimens. (2002) (109)
Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). (2008) (107)
Acute and late radiation injury in rhesus monkey parotid glands. Evidence of interphase cell death. (1986) (106)
Submandibular gland tumors. Adverse histologic factors and therapeutic implications. (1990) (106)
Receptor signaling as a regulatory mechanism of DNA repair. (2009) (105)
Chemoradiotherapy: Emerging treatment improvement strategies (2003) (104)
Hyperfractionated or accelerated radiotherapy for head and neck cancer. (2010) (104)
Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. (2013) (103)
Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. (2006) (99)
Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. (2002) (97)
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. (2012) (96)
Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? (2004) (96)
Squamous cell carcinoma of the maxillary sinus. (1993) (95)
In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. (2002) (93)
Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century (2013) (93)
Unilateral radiotherapy for the treatment of tonsil cancer. (2012) (92)
Inhalation anesthesia in experimental radiotherapy: a reliable and time-saving system for multifractionation studies in a clinical department. (1982) (91)
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. (2004) (90)
DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy (2011) (83)
Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. (2010) (81)
Radiation Induces Acute Alterations in Neuronal Function (2012) (79)
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. (2009) (79)
Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. (2013) (78)
Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck (2004) (78)
Is the rate of repair of radiation-induced sublethal damage in rat spinal cord dependent on the size of dose per fraction? (1987) (77)
Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: comparison of split-field and whole-field techniques. (2005) (77)
Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. (2007) (76)
Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. (1995) (75)
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. (2010) (73)
Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. (2006) (73)
Treatment of head and neck cancer. (2008) (73)
The kinetics of repair of sublethal damage in the rat cervical spinal cord during fractionated irradiations. (1984) (73)
Can positron emission tomography improve the quality of care for head-and-neck cancer patients? (2001) (72)
Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. (2005) (72)
A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. (2010) (71)
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. (2003) (71)
Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. (2007) (71)
Altered fractionation: limited by mucosal reactions? (1999) (70)
Unique radiosensitivity of serous cells in rhesus monkey submandibular glands. (1986) (70)
European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. (1988) (69)
Radiation myelopathy in primates treated with conventional fractionation. (1990) (68)
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. (2013) (67)
Radiotherapy for Head and Neck Cancers: Indications and Techniques (1993) (67)
Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. (2004) (67)
Postoperative radiotherapy for malignant tumors of the submandibular gland. (2001) (67)
Ethmoid sinus carcinomas: natural history and treatment results. (1998) (66)
An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). (2007) (65)
Response of parotid gland organ culture to radiation. (1989) (65)
Radiation therapy for early-stage carcinoma of the oropharynx. (2004) (65)
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. (2007) (65)
Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. (2005) (65)
The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. (2008) (64)
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. (2004) (64)
Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. (2012) (63)
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. (2006) (63)
Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. (2002) (63)
Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. (2015) (63)
From 2 Gy to 1 Gy per fraction: sparing effect in rat spinal cord? (1988) (63)
Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). (2014) (62)
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. (2012) (62)
Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. (2007) (60)
Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. (1997) (60)
The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group (2008) (60)
The role of apoptosis in radiation oncology (2009) (59)
Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. (1995) (57)
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. (2012) (57)
Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. (2011) (56)
Volume effects in rhesus monkey spinal cord. (1994) (56)
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. (1999) (56)
Long-term radiotherapy outcomes for nasal cavity and septal cancers. (2008) (55)
CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. (2006) (54)
Devices valuable in head and neck radiotherapy. (1992) (53)
Radiation therapy for nonmelanoma skin carcinomas. (1997) (52)
Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. (1995) (52)
Emotional well‐being does not predict survival in head and neck cancer patients (2008) (51)
Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. (1996) (50)
C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. (2003) (49)
Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. (2005) (48)
Assessment of epidermal growth factor receptor with 99mTc–ethylenedicysteine–C225 monoclonal antibody (2003) (47)
A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). (2012) (47)
Acute side effects and late complications after radiotherapy of localized carcinoma of the prostate. (1983) (47)
The effect of small radiation doses on the rat spinal cord: the concept of partial tolerance. (1983) (46)
Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. (1998) (46)
Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. (1995) (45)
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). (2011) (45)
Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer (2010) (44)
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. (2007) (44)
Radiation-induced apoptosis of oligodendrocytes in vitro. (1992) (43)
Head and neck carcinoma in the United States (2012) (42)
Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. (1996) (42)
Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials (2016) (41)
Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas. A pilot feasibility study of the Radiotherapy Group of the EORTC. (1982) (41)
Concomitant boost radiotherapy in the treatment of head and neck cancers (1992) (41)
Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & neck squamous cell carcinoma : a meta-analysis based on individual patient data (2002) (40)
Reemergence of apoptotic cells between fractionated doses in irradiated murine tumors. (1994) (40)
Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). (2014) (38)
The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy (2007) (38)
Clinical radiation doses for spinal cord: the 1998 international questionnaire. (2000) (38)
Carcinomas of the nasal cavity. (1992) (38)
Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. (2007) (38)
Head and Neck: Editorial (2001) (37)
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. (2009) (37)
Radiation nephropathy in the rhesus monkey: morphometric analysis of glomerular and tubular alterations. (1995) (36)
Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx (2005) (36)
Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. (2011) (35)
Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. (2006) (34)
Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma (2005) (34)
Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings (2003) (33)
The relationship between apoptosis and atrophy in the irradiated lacrimal gland. (1992) (33)
Interobserver reliability of computed tomography‐derived primary tumor volume measurement in patients with supraglottic carcinoma (2005) (33)
Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. (2012) (33)
Acute radiation injury of ocular adnexa. (1988) (33)
Phase II Multi-institutional Study of Intensity Modulated Radiation Therapy (IMRT) +/− Chemotherapy for Nasopharyngeal (NPC) Carcinoma: Preliminary Clinical Results of RTOG 0225 (2008) (32)
Workshop report: Organ preservation strategies in advanced head and neck cancer—Current status and future directions (1999) (32)
Current Topics in Clinical Radiobiology of Tumors (1993) (32)
Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. (1987) (31)
Concomitant chemotherapy and radiation therapy certainly improves local control. (2005) (31)
Low grade astrocytoma in children treated by surgery and radiation therapy. (1984) (29)
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial (2016) (29)
Radiation‐induced morphologic changes in the rhesus monkey (Macaca mulatta) brain (2001) (28)
A modified radiotherapy technique in the treatment of medulloblastoma. (1984) (28)
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. (2017) (28)
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma (2007) (28)
Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. (2014) (27)
Innovative prevention strategies for radiation necrosis of the central nervous system. (2002) (27)
Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. (2003) (25)
Risk factors for clinician‐reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129 (2014) (25)
The tolerance to multiple daily fractionated radiotherapy for the treatment of prostatic and bladder carcinoma: a feasibility study. (1982) (25)
Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. (2004) (24)
Skin graft survival after external beam irradiation. (1999) (24)
Radiation myelopathy: new perspective on an old problem. (1999) (24)
The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. (2013) (23)
Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? (2004) (23)
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. (2015) (23)
Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck (1995) (22)
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. (2010) (22)
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo (2011) (22)
Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) (2009) (22)
Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis. (2006) (21)
The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation. (2012) (21)
A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. (2002) (21)
A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. (2005) (21)
Gastrostomy Tubes Decrease by Over 50% With Intensity Modulated Proton Therapy (IMPT) During the Treatment of Oropharyngeal Cancer Patients: A Case–Control Study (2013) (20)
26: A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma of The Vocal Cord (2006) (20)
Toward improving the therapeutic ratio in stereotactic radiosurgery: selective modulation of the radiation responses of both normal tissues and tumor. (2007) (19)
Peripheral Nerve Regeneration: The Effects of Postoperative Irradiation (1997) (19)
Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. (1994) (19)
Radiotherapy in multiple fractions per day for prostatic carcinoma: late complications. (1986) (17)
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation. (1995) (17)
Modification of radiation response : cytokines, growth factors, and other biological targets (2003) (17)
Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. (2009) (17)
Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234 (2008) (17)
Longitudinal oncology registry of head and neck carcinoma (LORHAN®): initial supportive care findings (2009) (17)
p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). (2013) (16)
Accelerated fractionation: what is the price for speeding? (1997) (16)
Radiation response of the monkey kidney following contralateral nephrectomy. (1994) (16)
108Overall time factor in postoperative radiation: Results of a prospective randomized trial (1996) (15)
Radiation Therapy Oncology Group (RTOG) Altered Fractionation Trials (1995) (15)
Effects of Insulin-Like Growth Factor-1 (IGF-1) and Amifostine in Spinal Cord Reirradiation (2005) (15)
IMMUNOLOGICAL AND CLINICAL OBSERVATIONS IN DIABETIC KIDNEY GRAFT RECIPIENTS PRETREATED WITH TOTAL‐LYMPHOID IRRADIATION (1987) (14)
Combining molecular therapeutics with radiotherapy for head and neck cancer (2008) (14)
Potential role of growth factors in diminishing radiation therapy neural tissue injury. (2005) (14)
Preliminary results of intensity modulated radiation therapy for small primary oropharyngeal carcinoma (2003) (14)
Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): Final analysis (2004) (14)
Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy (2003) (14)
Prevention and management of radiation myelopathy. (1994) (14)
Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: Results of a Correlative Study From the Radiation Therapy Oncology Group (RTOG) 90-03 Trial (2007) (13)
Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. (2010) (13)
Role of Epidermal Growth Factor Receptor and Its Inhibition in Radiotherapy (2003) (13)
79 : Phase II Multi-institutional Study of IMRT for Oropharyngeal Cancer (RTOG 00-22): Early Results (2006) (13)
Postoperative irradiation: are there long-term effects on nerve regeneration? (1999) (12)
Associations between Radiation Doses to Pharyngeal Regions and Severe Late Toxicity in Head and Neck Cancer Patients Treated With Concurrent Chemoradiotherapy–An RTOG Analysis (2007) (11)
Elevated levels of plasminogen activators in the pathogenesis of delayed radiation damage in rat cervical spinal cord in vivo. (1994) (11)
Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. (2011) (11)
The synergistic effect of total-lymphoid irradiation with extracted donor alloantigen in inducing transplantation unresponsiveness. (1989) (11)
103 Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma (1995) (11)
The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab (2005) (11)
Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) (2007) (11)
Intensity modulated radiation therapy (IMRT) for metastatic cervical adenopathy from oropharynx carcinoma (2004) (11)
Advances in Radiation Therapy (1998) (10)
Modulation of fibrinolysis by ionizing radiation (2005) (10)
Phase II Multi-Institutional Study of IMRT ± Chemotherapy for Nasopharyngeal Carcinoma (RTOG 0225): Preliminary Results (2007) (10)
Radiation Injury to the Central Nervous System: Clinical Features and Prevention (1999) (10)
Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Update of RTOG 9911 (2005) (10)
Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. (2007) (10)
30 : Prediction of Neck Dissection (ND) Requirement Following Definitive Radiotherapy (RT) for Head And Neck Squamous Cell Carcinoma (HNSCC) (2006) (9)
A morphometric analysis of glomerular and tubular alterations following fast-neutron irradiation of the pig and monkey kidney. (1998) (9)
Modification of Radiation Response (2003) (9)
Phase II Study of Paclitaxel and Cisplatin in Combination with Split Course Concomitant Hyperfractionated Re-Irradiation in Patients with Recurrent Squamous Cell Cancer of the Head and Neck: Results of RTOG 99-11 (2005) (9)
Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer (2004) (9)
Tissue repair and repopulation in the tumor bed effect. (1988) (9)
P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003. (2003) (8)
Tolerance of rhesus monkey liver to ionizing radiation (1993) (8)
Intensity Modulated Proton Therapy for Head-and-Neck Cancer: The First Clinical Experience (2012) (8)
144 CpG oligodeoxynucleotides (CpG ODNS) are potent enhancers of radio- and chemoresponses of murine tumors (2006) (8)
Epidermal growth factor receptor as a target to improve treatment of lung cancer. (2004) (8)
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma : Results of a matched cohort study (1997) (8)
Apoptosis In Vivo (2011) (8)
Role of Cyclooxygenase-2 (COX-2) and Its Inhibition in Tumor Biology and Radiotherapy (2003) (7)
Decreased levels of glia-derived nexin/protease nexin I in irradiated rat spinal cord in vivo. (1993) (7)
Radiation-induced anatomic changes during fractionated head & neck radiotherapy: a pilot study using an integrated CT-LINAC system (2003) (7)
Proliferation kinetics of a murine fibrosarcoma during fractionated irradiation. (1988) (7)
Peripheral nerve regeneration: the effects of postoperative irradiation. (1997) (7)
101 Impact of risk factors and total time for combined surgery and radiotherapy on the outcome of patients with advanced head and neck cancer (1999) (7)
Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome. (2012) (6)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN), a new national cancer registry. (2007) (6)
Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer (2007) (6)
Patient-reported fatigue in head and neck cancer survivors. (2011) (5)
Feasibility of economic analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare data. (2011) (5)
EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. (2006) (5)
In vitro analysis of T cell-mediated cytotoxicity displayed by rat heart allograft recipients rendered unresponsive by total-lymphoid irradiation and extracted donor antigen. (1990) (5)
RTOG 90-03: Final Report (2012) (5)
Sinonasal carcinoma with neuroendocrine differentiation: patterns of failure according to histologic phenotype (2003) (5)
993PDASSOCIATION OF HUMAN PAPILLOMAVIRUS (HPV) AND P16 STATUS WITH EFFICACY AND SAFETY DATA IN THE PHASE III RADIOTHERAPY (RT)/CETUXIMAB (CET) REGISTRATION TRIAL FOR LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LASCCHN). (2014) (4)
In response to Drs. Dubben, Beck-Bornholdt, and Llogie. (2002) (4)
Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. (2006) (4)
Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer (2006) (4)
A Region-of-Interest Analysis of Setup Uncertainties in Head and Neck Radiotherapy (2005) (4)
Should Hypopharynx Cancer Continue to be Included in “Multi-Head and Neck” Trials within the RTOG? (2010) (4)
Inter-observer Contouring Variations of Head-and-Neck Anatomy (2005) (4)
Feasibility of multiple daily fractionation in high dose radiotherapy of malignant gliomas (1981) (4)
50 Mucosal melanoma of the head and neck (1997) (4)
Outcome comparisons of four radiation therapy oncology group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: Encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT). (2004) (4)
Concomitant Boost Radiation and Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Update of a Phase II Trial of the RTOG (99-14) (2005) (4)
Larynx and Hypopharynx Cancer (2011) (4)
Outcomes and Risk Factors in Patients Treated with Surgery and Postoperative Radiation Therapy Alone: A Subset Update of a Randomized Trial (2011) (3)
Hyperfractioned or accelerated radiotherapy in head and neck cancer: a meta‐analysis (2007) (3)
An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. (2013) (3)
Influence of fraction size on local control and complication rates in definitive radiotherapy for stage tz glottic cancer (1990) (3)
Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction Following Oropharyngeal IMRT (2014) (3)
Intensity Modulated Radiation Therapy for Squamous Cell Carcinoma Metastatic to Cervical Lymph Nodes From an Unknown Primary Site; Outcomes and Patterns of Failure (2007) (3)
Head and Neck Tumors: Overview (2011) (3)
The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129. (2012) (3)
Valproic Acid Shows Normal Tissue Protection in a Rat Spinal Cord Model (2008) (3)
Erratum: Improved survival using intensity‐modulated radiation therapy in head and neck cancers: A SEER‐Medicare analysis (2014) (3)
[Biological prevention and/or therapy possibility of radiation myelopathy. A discussion of recent perspectives]. (1999) (3)
Magnetic resonance imaging of the central nervous system of the rhesus monkey. (1997) (3)
VEGF (vascular endothelial growth factor) modulates the development of radiation myelopathy (RM) in rats (2001) (3)
[Experimental data for administration of insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) for prevention of radiation myelopathy]. (2002) (3)
Real-time Peer Review Quality Assurance Conferences Incorporating Physical Examination for Head-and-Neck Cancer Radiation Therapy Result in Clinically Meaningful Target Volume Alteration: Results of a Prospective Volumetric Analysis (2012) (3)
IMRT for Oropharyngeal Carcinoma: Patient Outcomes and Patterns of Failure (2011) (3)
Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). (2010) (3)
Radiotherapy for head and neck neoplasms. (1993) (3)
Mucosal Melanoma of the Head and Neck Clinical Practice Guidelines in Oncology (2012) (2)
INTEGRATING RADIOTHERAPY WITH EGFR ANTAGONISTS AND OTHER MOLECULAR THERAPEUTICS FOR THE TREATMENT OF HEAD AND NECK CANCER (2007) (2)
Treatment, patient and tumor characteristics impact quality of life (QOL) in patients with locally advanced head and neck cancer: Report of the radiation therapy oncology group (RTOG) trial 90-03 (2001) (2)
Pre- and Postinduction Chemotherapy Target Volume Delineation in Head and Neck Cancer: Preliminary Results from an Expert Panel (2009) (2)
Early postoperative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy (RT) (phase II trial RTOG H-0024) is well tolerated for patients with resected, high-risk squamous carcinoma of the head and neck (HNSCC) (2004) (2)
Long-term symptom burden after radiation treatment for oropharynx cancer: A comparison of 3D and IMRT techniques. (2011) (2)
Key lessons from intensity modulated radiation therapy (IMRT) for thyroid cancer (2004) (2)
Interfractional Movement of the Larynx and Oropharynx during Radiotherapy (2009) (2)
Overexpression of the epidermal growth factor receptor (EGFR), as determined by EGFR immunostaining on tissue microarrays, fails to demonstrate prognostic value for patients with glioblastoma multiforme: a report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806 (2002) (2)
Longitudinal oncology registry of head and neck carcinoma (LORHAN): First report of outcomes. (2016) (2)
Prospective Experience with CT-guided Adaptive Radiotherapy for Head-and-Neck Cancer (2009) (2)
Is substance P a mediator of radiation slaloadenitis? (1995) (2)
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation (XRT) in recurrent squamous cell carcinoma of the head and neck (SCCHN): Long-term follow-up of Radiation Therapy Oncology Group (RTOG) protocol 9911. (2012) (2)
P09 01 SP – DEPENDENCE OF SPINAL CORD RESPONSE ON IRRADIATED LENGTH AND LEVEL (1991) (2)
Chapter 39 – Cutaneous Carcinoma (2012) (2)
Deforming intensity distributions to incorporate inter-fraction anatomic variations for image-guided IMRT (2004) (2)
PD-036: Association of HPV/p16 status with efficacy and safety in pts with OPC in the phase 3 RT/cetuximab registration trial (2015) (2)
Prognostic Nomograms for Toxicity and Survival After Head and Neck Cancer Reirradiation and Chemotherapy: A Secondary Analysis of RTOG 9610 and 9911 (2014) (2)
2364 : IMRT Re-Irradiation for Locoregionally Recurrent or In-Field Second Primary Head and Neck Cancer (2006) (2)
Cost-utility analysis of rtog 90-03: phase iii randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma (2001) (2)
RTOG 0324: A Phase II Study of Cetuximab (C225) in Combination With Chemoradiation (CRT) in Patients (PTS) With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): Correlation Between EGFR Expression and the Patients' Outcome (2007) (2)
The reliability and validity of the M. D. Anderson Symptom Inventory (MDASI-HN) as a measure of symptom burden in the head and neck cancer (HNC) patient population (2005) (2)
Post-operative External Beam Radiotherapy for Differentiated Thyroid Cancer: Modern Era Outcomes and Morbidity (2008) (1)
High dose multiple daily fractionation radiotherapy in combination with misonidazole as a treatment of high grade malignant gliomas. A pilot study of the radiotherapy group of the E.O.R.T.C. (1981) (1)
Reirradiation of Head-and-Neck Cancers: An MD Anderson Update (2013) (1)
Microvessel density (mvd)≥60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial (2001) (1)
409 Postoperative radiation for advanced head and neck cancers (1995) (1)
Prognostic significance of COX-2 expression in advanced head and neck cancer treated with radiotherapy in a phase III RTOG trial (90-03) (2001) (1)
Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Results of RTOG 9911. (2004) (1)
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. (2007) (1)
Long-term Outcomes for T3 Larynx Squamous Cancers (2008) (1)
Effects of Therapy on Central Nervous System Functions in Children (1994) (1)
Multi-institutional Trial of IMRT for Early Stage Oropharyngeal Cancer: Acceleration via Simultaneously Incorporated Boost (SIB) (RTOG 00-22) (2008) (1)
Comparison Between IMRT and 3D CRT in Laryngeal Cancer Patients Treated on RTOG 0522 (2013) (1)
STRATEGIES IN ADVANCED HEAD AND NECK CANCER — CURRENT STATUS AND FUTURE DIRECTIONS (1999) (1)
4 Year Experience of Intensity Modulated Radiotherapy (IMRT)for tumors of the Nasal Cavity, Paranasal Sinuses and Orbit (2005) (1)
The TAME Risk Classification System: Acute Toxicity Burden and IPD Analysis of RTOG 90–03 (2005) (1)
Acute vitamin B1 deficiency (wernicke's encephalopathy) in connection with radiotherapy for oral cavity cancer. (1981) (1)
P09 12 SP – RADIATION-INDUCED APOPTOSIS OF GLIAL CELLS IN VITRO (1991) (1)
2820 Association of p16 status and feeding tube use in patients with locoregionally advanced squamous cell cancer of the head and neck treated with radiotherapy +/- cetuximab in a phase III study (2015) (1)
Predictive Biomarkers and Personalized Medicine TP 53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence (2011) (1)
Tumor bed irradiation enhances sensitivity of A431 tumor xenografts to C225 anti-EGFR antibody (2008) (1)
Mechanisms and Modification of the Radiation Response of the Central Nervous System (2003) (1)
Inhibition of DNA-end binding complex formation as a mechanism for celecoxib-induced radioenhancement in human head and neck carcinoma cells (2004) (1)
RADIATION THERAPY ONCOLOGY GROUP RTOG 0619 A RANDOMIZED PHASE II TRIAL OF CHEMORADIOTHERAPY VERSUS CHEMORADIOTHERAPY AND VANDETANIB FOR HIGH-RISK POSTOPERATIVE ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (2010) (1)
Integrating EGFR Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head and Neck Squamous Cell Carcinoma (2011) (1)
Impact of Metformin on Outcomes in Patients With Oropharynx Cancer Treated With IMRT (2012) (1)
In Reply to Dr. Christiansen et al. (2009) (1)
Surrogate endpoints for overall survival (OS) in head and neck squamous cell carcinoma (HNSCC): Evaluation using individual data of 23,737 patients (2007) (1)
Adverse Histologic Factors and Therapeutic Implications (2017) (1)
Long-term Outcomes from RTOG 99-03: Radiation Therapy With or Without Erythropoietin for Anemic Head-and-Neck Cancer Patients (2012) (1)
Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy. (2010) (1)
Longitudinal oncology registry of head and neck carcinoma (LORHAN): Initial treatment findings (2008) (1)
Inverse Relationship between Epidermal Growth Factor Receptor Expression and Radiocurability of Murine Carcinomas 1 (1999) (1)
The Influence of Accrual Volume and National Cancer Institute-Comprehensive Cancer Center (NCI-CCC) Designation on Outcome for the RTOG 91-11 Intergroup Trial for Laryngeal Preservation (2007) (1)
Impact of EGFR expression on the response of advanced head and neck carcinomas to concomitant boost radiotherapy in a RTOG phase III trial (90-03) (2003) (1)
98 Long term results of the concomitant boost fractionation schedule for treatment of oropharyngeal carcinoma (1999) (1)
Long-term Outcomes for T4 Larynx Cancer (2008) (1)
Post-Operative Radiation for Maxillary Sinus Carcinoma: Does Elective Nodal Irradiation Affect Regional Control? (2005) (1)
Comparison of intensity modulated radiotherapy versus conventional treatment planning in bilateral and unilateral postoperative thyroid cancer (2003) (0)
Chapter 14 – The Orbit (2010) (0)
Abstract 2487: A multi-kinase inhibitor, XL228, enhanced human cancer cell radiosensitivity and suppressed cell invasion and migration (2011) (0)
Role of cyclin D1 in tumor radioresponse (2000) (0)
Results of radiation for early-stage carcinoma of the oropharynx (2003) (0)
OP064: Reirradiation of head and neck cancers with IMRT: Updated outcomes and analysis (2013) (0)
Inhibition of IGF-1R Signaling Enhances the Head and Neck Tumor Radioresponse but Fails to Further Improve Tumor Response to Cetuximab and Radiation Therapy In Vivo (2014) (0)
Perineural invasion infers poor therapeutic outcome and prophylactic neck irradiation posts no benefit (2003) (0)
Pattern of symptoms in head and neck cancer (HNC) survivors treated with radiation therapy (RT): Association with systemic therapy. (2012) (0)
Correlation of EGFR Expression by IHC and FISH to Predict Patient Outcome: A Phase II RTOG 0324 Study for Patients with Stage III NSCLC Treated by Chemoradiotherapy and Cetuximab (C225) (2008) (0)
Comprar Radiotherapy for Head and Neck Cancers, 4/e | Adam S. Garden | 9781608316861 | Lippincott Williams & Wilkins (2011) (0)
K5. Progress in customizing head and neck cancer therapy (2011) (0)
Abstract 488: cSrc is a radioresistance molecule in cancer radiotherapy: cSrc-siRNA transfection augments tumor cell radiosensitivity in vitro and chemical inhibition of Src kinases increases tumor response to radiation (2010) (0)
SP-031: Update of R-TOG 0522. A Randomised Phase III Trial of Concurrent Accelerated Radiation and Cispltin Versus Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) for State III and IV Head and Neck Carcinomas (2013) (0)
Laryngeal squamous cell carcinoma: Early-stage disease (2008) (0)
Abstract 2509: Preclinical evaluation of the effects of cilengitide, an inhibitor of integrins, in sensitizing human solid cancer xenografts to radiation (2011) (0)
2416 : Radiation Therapy for Squamous Cell Carcinoma of the Eyelid (2006) (0)
2782: Deformable Image Registration for Cone-Beam CT (CBCT) Images for Implemantion of Image-Guided Adaptive Radiotherapy (2006) (0)
319 Strategies to offset tumor clonogen proliferation (1995) (0)
Intersociety Radiation Oncology Summit-SCOPE II. (2008) (0)
TP53 Disruptive Mutations Lead to Increased Loco-regional Recurrence following Radiation and In Vitro Radioresistance by Decreasing Accelerated Senescence (2011) (0)
CUSTOMIZING THERAPY FOR HPV-NEGATIVE HEAD AND NECK CARCINOMA (2011) (0)
2852: Optimizing Head and Neck Radiation Treatment Planning Using an IMRT Monoisocentric Technique with a Static Low Anterior Neck Field (2006) (0)
Does FDG-PET/CT Provide Added Value over CT Alone for Assessment of Radiation Response in Advanced Stage Head and Neck Cancer? (2008) (0)
Abstract 2488: Co-targeting EGFR and IGF-1R to sensitize or overcome induced resistance of head and neck cancer models to radiation (2011) (0)
Combinations of Taxanes and Ionizing Radiation (2006) (0)
351 POSTER Identification of kinases that are potential molecular determinants of cellular response to radiation using antibody arrays (2008) (0)
The Kutler/Patel/Shah article reviewed (2004) (0)
Phase II study of polymyxin B, tobramycin, and clotrimazole to prevent oral irradiation mucositis (1996) (0)
Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer. (2010) (0)
The impact of baseline nutritional support on treatment outcome in patients with locally advanced squamous cell cancer of the head and neck treated with definitive radiotherapy: report of the radiation therapy oncology group (RTOG) trial 90-03 (2002) (0)
317 Schedule Dependent Tumor Cell Response to Radiation When Combined with Anti-IGF1R and Anti-EGFR Antibodies (2012) (0)
Advances in radiation therapy. Introduction. (1998) (0)
E16 - Integration of molecular targeting with radiotherapy: Recent achievements and improvement strategies (2007) (0)
MiRNA and mRNA Expression Profiling in Head and Neck Squamous Cell Carcinoma Reveals Aberrantly Expressed miRNA That May Have Prognostic Potential (2009) (0)
The TAME adverse event summary and risk classification system: Analysis of the RTOG H&N Database (2005) (0)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care. (2011) (0)
In reply [10] (2007) (0)
2109 Radiotherapy for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site (1996) (0)
Correlating Survival with Radiographic Response to Radiotherapy for Head-and-Neck Cancer Patients: FDG-PET/CT is not Superior to CT Alone (2009) (0)
324 BIOMARKERS FOR HEAD AND NECK CARCINOMA (2012) (0)
Post-operative radiation for maxillary sinus carcinomas in the modern era (2001) (0)
Predictors on Longitudinal Changes of Clinician Reported Symptom Clusters Identified in Patients with Head and Neck Cancer Treated on RTOG Trials (2011) (0)
Improved Survival Using IMRT in Head-and-Neck Cancers: A SEER-Medicare Analysis (2013) (0)
Head and Neck CancersPractice Guidelines in Oncology (2011) (0)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN), a new national cancer registry (2006) (0)
311 TUMOR MICROENVIRONMENT AND INTEGRINS AS EFFECTIVE THERAPEUTIC TARGETS TO IMPROVE RADIOTHERAPY OUTCOME (2012) (0)
Commentary (Corry et al): The Role of Neck Dissection Following Definitive Chemoradiation (2004) (0)
Impact of IMRT Use on Survival of Patients With Head-and-Neck Cancer Treated With Radiation: A SEER-Medicare Analysis (2014) (0)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Preliminary Report Regarding Radiation Patterns of Care (2008) (0)
PD12. Human papillomavirus-associated head and neck carcinoma: Epidemiology and biology (2011) (0)
Predictive Biomarkers and Personalized Medicine DNA Repair Biomarker Profiling of Head and Neck Cancer : Ku 80 Expression Predicts Locoregional Failure and Death following Radiotherapy (2011) (0)
Effect of combined AZQ and radiation on the tolerance of the rat spinal cord (1986) (0)
The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG (2008) (0)
A pan Her inhibitor, BMS-599626, augments radiosensitivity of HN5 cells by increasing radiation-induced apoptosis and inhibiting DNA repair. (2007) (0)
Head and neck cancers. (2005) (0)
P16 30 MP – TEMPORAL AND DOSE RESPONSES OF APOPTOSIS IN RADIOSENSITIVE AND RADIORESISTANT MURINE TUMORS (1991) (0)
Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy (2012) (0)
Combination of insulin-like growth factor-1 (IGF-1) and amifostine increases the tolerance of the spinal cord to re-irradiation (2001) (0)
Does immune compromised state influence tumor control in patients with epithelial skin cancer of the head and neck region (2003) (0)
Patient-reported symptoms following IMRT alone for oropharynx cancer: A survivorship study. (2012) (0)
115 : The Addition of Chemotherapy to Radiation Is Cost-Effective in the Treatment of Patients With Locally Advanced Laryngeal Cancer: An Economic Analysis of Radiation Therapy Oncology Group (RTOG) 91-11 (2006) (0)
Abstract 4895: P16INK4A, a surrogate marker of HPV infection and prognosis for head and neck cancer, delays DNA damage repair and enhances radiation response (2014) (0)
Loss of Fhit expression in head and neck squamous cell carcinoma and its utility in individualized therapy. (2004) (0)
SU‐EE‐A3‐06: Deformable Image Registration in Cone‐Beam CT Images for Image‐Guided Adaptive Radiotherapy (2006) (0)
Hyperfractionated or accelerated radiotherapy in head and neck cancer : a fractional benefit? Commentary : a meta-analysis. Commentary (2006) (0)
54 Prognostic determinants of nasopharyngeal cancer treated by radiotherapy alone: Results of a multivariate analysis on 378 patients (1996) (0)
504 Post-operative radiation therapy for advanced head and neck cancers (1996) (0)
Skin Culture and Treatment Results in Head and Neck Cancer Patients with Severe Radiation Dermatitis and Potential Suprainfection (2010) (0)
Influence of splenectomy on the induction of transplantation tolerance after total lymphoid irradiation (TLI) in mice (1986) (0)
WE‐E‐T‐617‐02: Dosimetric Impact of Anatomic Variations for Head & Neck Cancer Patients Undergoing IMRT Treatment Analyzed by Deformable Imaging Registration (2005) (0)
Response to Letter by Dr. Ibott et al. (2010) (0)
P18 06 MP – PATHOGENESIS OF ATROPHY OF THE IRRADIATED LACRIMAL GLAND (1991) (0)
Letter to the editor [2] (1995) (0)
The Choice between Altered Fractionation and Radio-Chemotherapy for Head and Neck Carcinoma (2002) (0)
Parotid gland dose in head-and-neck intensity-modulated radiotherapy: Is what you plan what you get? (2008) (0)
Comparison of intra-arterial cisplatin and radiation therapy (RT) to other radiation therapy oncology group (RTOG) regimens using standard or accelerated RT with or without concurrent chemotherapy in patients with stage IV-T4 head and neck cancer (2004) (0)
Abstract 4435: Targeting Met signaling to overcome human cancer cell resistance to radiation. (2013) (0)
Characteristics and Clinical Outcomes of Patients with Multiple Potentially HPV-Related Malignancies (2010) (0)
Definitive radiotherapy in basaloid squamous cell carcinoma of the head and neck; need for more aggressive modalities? (2006) (0)
Chapter 34 – Sinonasal Cancer (2012) (0)
Radiation therapy oncology: In regard to Fu et al., IJROBP 2000;48:7-16 [6] (multiple letters) (2002) (0)
235 Valproic acid as a radiation protector in a rat spinal cord damage model (2006) (0)
SU‐E‐J‐99: Multi‐Atlas Based Auto‐Segmentation of Low‐Risk Clinical Target Volume (CTV) for Head‐and‐Neck Radiotherapy (2011) (0)
OC-016: Patient reported outcomes (PRO) of RTOG 9003 (2015) (0)
Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity (2012) (0)
Effect of combined A Z Q and radiation on the tolerance of the rat spinal cord (0)
Patterns of Disease Recurrence following Radiation for Oropharyngeal Cancer (2009) (0)
Conditional Survival for Locally Advanced Larynx Cancer (2011) (0)
M.D. Anderson consensus guidelines for head and neck target volume determination and delineation (2004) (0)
Abstract 2507: Triple agent therapy combining radiation with AMG479 (IGF1R antibody) and panitumumab (EGFR antibody) in a head and neck tumor model (2011) (0)
Symptom Burden during Radiation Therapy and Chemoradiation for Head and Neck Cancer (2010) (0)
2659 : Inhibition of VEGFR-1, -2, and -3 Signaling by AZD2171 Enhances the Anti-Tumor Efficacy of Radiation Therapy in a Mouse Xenograft Model (2006) (0)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Findings related to the oropharynx. (2010) (0)
A Gene Expression Signature Predicts Recurrence-free Survival and Overall Survival for High-risk Surgical-pathologic Head and Neck Squamous Cell Carcinomas following Post-operative Radiotherapy (2010) (0)
Chapter 5 – Principles of Combining Radiation Therapy and Molecular Therapeutics (2010) (0)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set. (2010) (0)
ASTRO Presidential Address “Sculpting the Landscape of Radiation Oncology” (2006) (0)
P09 07 SP – TOLERANCE OF SPINAL CORD TO RE-IRRADIATION (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With K. Kian Ang?

K. Kian Ang is affiliated with the following schools:

University of Calgary
Hasselt University
MD Anderson Cancer Center
McMaster University
Vanderbilt University
University of South Florida
Thomas Jefferson University
University of Texas Southwestern Medical Center

K. Kian Ang's Academic­Influence.com Rankings

Why Is K. Kian Ang Influential?

K. Kian Ang's Published Works

Published Works

What Schools Are Affiliated With K. Kian Ang?

K. Kian Ang's AcademicInfluence.com Rankings